Download PDF
Semin Thromb Hemost 2010; 36(6): 653-659
DOI: 10.1055/s-0030-1262887
© Thieme Medical Publishers

Transplantation in Atypical Hemolytic Uremic Syndrome

David Kavanagh1 , Anna Richards2 , Tim Goodship1 , Hannu Jalanko3
  • 1Institute of Human Genetics, Newcastle University, United Kingdom
  • 2MRC Centre for Inflammation Research, Queens Medical Research Institute, Edinburgh, United Kingdom
  • 3Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland
Further Information

Publication History

Publication Date:
23 September 2010 (online)

  Permissions and Reprints

ABSTRACT

Atypical hemolytic uremic syndrome (aHUS) is a disease characterized by overactivation of complement. Recurrence following renal transplantation is determined by a genetic predisposition. Genetic screening of all individuals with aHUS should be performed prior to listing for transplantation. Individuals with isolated mutations in MCP have a low risk of recurrence and may be considered for kidney transplantation alone. In individuals with CFH and CFI mutations, the risk of recurrence following renal transplantation is high. Combined liver/kidney transplantation has been used successfully in individuals with CFH mutations following the introduction of perioperative plasma exchange; however, such a procedure is not without its risks. Liver/kidney transplantation has yet to be performed on individuals with CFI and C3 mutations but may be predicted to be successful. In individuals with CFH autoantibodies, a reduction in titer through plasma exchange and rituximab has been successful. Clinical trials of the complement C5 inhibitor eculizumab may improve prospects for isolated renal transplantation in individuals with complement protein mutations.

KEYWORDS

Transplantation - hemolytic uremic syndrome - complement - factor H - eculizumab

REFERENCES

  • 1 Kavanagh D, Richards A, Atkinson J. Complement regulatory genes and hemolytic uremic syndromes.  Annu Rev Med. 2008;  59 293-309
    CrossrefPubMedSearch in Google Scholar
  • 2 Richards A, Buddles M R, Donne R L et al. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition.  Am J Hum Genet. 2001;  68(2) 485-490
    CrossrefPubMedSearch in Google Scholar
  • 3 Caprioli J, Bettinaglio P, Zipfel P F Itaslian Registry of Familial and Recurrent HUS/TTP et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20.  J Am Soc Nephrol. 2001;  12(2) 297-307
    PubMedSearch in Google Scholar
  • 4 Pérez-Caballero D, González-Rubio C, Gallardo M E et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome.  Am J Hum Genet. 2001;  68(2) 478-484
    CrossrefPubMedSearch in Google Scholar
  • 5 Dragon-Durey M A, Frémeaux-Bacchi V, Loirat C et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases.  J Am Soc Nephrol. 2004;  15(3) 787-795
    CrossrefPubMedSearch in Google Scholar
  • 6 Frémeaux-Bacchi V, Dragon-Durey M A, Blouin J et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome.  J Med Genet. 2004;  41(6) e84
    CrossrefPubMedSearch in Google Scholar
  • 7 Kavanagh D, Kemp E J, Mayland E et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2005;  16(7) 2150-2155
    CrossrefPubMedSearch in Google Scholar
  • 8 Caprioli J, Noris M, Brioschi S International Registry of Recurrent and Familial HUS/TTP et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.  Blood. 2006;  108(4) 1267-1279
    CrossrefPubMedSearch in Google Scholar
  • 9 Richards A, Kemp E J, Liszewski M K et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.  Proc Natl Acad Sci U S A. 2003;  100(22) 12966-12971
    CrossrefPubMedSearch in Google Scholar
  • 10 Noris M, Brioschi S, Caprioli J International Registry of Recurrent and Familial HUS/TTP et al. Familial haemolytic uraemic syndrome and an MCP mutation.  Lancet. 2003;  362(9395) 1542-1547
    CrossrefPubMedSearch in Google Scholar
  • 11 Frémeaux-Bacchi V, Moulton E A, Kavanagh D et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2006;  17(7) 2017-2025
    CrossrefPubMedSearch in Google Scholar
  • 12 Ståhl A L, Kristoffersson A, Olin A I et al. A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome.  Mol Immunol. 2009;  46(11-12) 2236-2243
    CrossrefPubMedSearch in Google Scholar
  • 13 Delvaeye M, Noris M, De Vriese A et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  361(4) 345-357
    CrossrefPubMedSearch in Google Scholar
  • 14 Moore I, Strain L, Pappworth I et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.  Blood. 2010;  115(2) 379-387
    CrossrefPubMedSearch in Google Scholar
  • 15 Józsi M, Licht C, Strobel S et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency.  Blood. 2008;  111(3) 1512-1514
    CrossrefPubMedSearch in Google Scholar
  • 16 Dragon-Durey M A, Loirat C, Cloarec S et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2005;  16(2) 555-563
    CrossrefPubMedSearch in Google Scholar
  • 17 Frémeaux-Bacchi V, Miller E C, Liszewski M K et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.  Blood. 2008;  112(13) 4948-4952
    CrossrefPubMedSearch in Google Scholar
  • 18 Goicoechea de Jorge E, Harris C L, Esparza-Gordillo J et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.  Proc Natl Acad Sci U S A. 2007;  104(1) 240-245
    CrossrefPubMedSearch in Google Scholar
  • 19 Caprioli J, Castelletti F, Bucchioni S International Registry of Recurrent and Familial HUS/TTP et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease.  Hum Mol Genet. 2003;  12(24) 3385-3395
    CrossrefPubMedSearch in Google Scholar
  • 20 Frémeaux-Bacchi V, Kemp E J, Goodship J A et al. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts.  J Med Genet. 2005;  42(11) 852-856
    CrossrefPubMedSearch in Google Scholar
  • 21 Blom A M, Bergström F, Edey M et al. A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity.  J Immunol. 2008;  180(9) 6385-6391
    PubMedSearch in Google Scholar
  • 22 Zipfel P F, Edey M, Heinen S et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome.  PLoS Genet. 2007;  3(3) e41
    CrossrefPubMedSearch in Google Scholar
  • 23 Noris M, Remuzzi G. Hemolytic uremic syndrome.  J Am Soc Nephrol. 2005;  16(4) 1035-1050
    CrossrefPubMedSearch in Google Scholar
  • 24 Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children.  Pediatr Nephrol. 2003;  18(11) 1095-1101
    CrossrefPubMedSearch in Google Scholar
  • 25 Ferraris J R, Ramirez J A, Ruiz S et al. Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation.  Pediatr Nephrol. 2002;  17(10) 809-814
    CrossrefPubMedSearch in Google Scholar
  • 26 Loirat C, Frémeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation.  Pediatr Transplant. 2008;  12(6) 619-629
    CrossrefPubMedSearch in Google Scholar
  • 27 Bresin E, Daina E, Noris M International Registry of Recurrent and Familial HUS/TTP et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background.  Clin J Am Soc Nephrol. 2006;  1(1) 88-99
    CrossrefPubMedSearch in Google Scholar
  • 28 Sellier-Leclerc A L, Frémeaux-Bacchi V, Dragon-Durey M A French Society of Pediatric Nephrology et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2007;  18(8) 2392-2400
    CrossrefPubMedSearch in Google Scholar
  • 29 Kavanagh D, Goodship T H. Membrane cofactor protein and factor I: mutations and transplantation.  Semin Thromb Hemost. 2006;  32(2) 155-159
    Thieme ConnectPubMedSearch in Google Scholar
  • 30 Schmidt C Q, Herbert A P, Kavanagh D et al. A new map of glycosaminoglycan and C3b binding sites on factor H.  J Immunol. 2008;  181(4) 2610-2619
    CrossrefPubMedSearch in Google Scholar
  • 31 Ferreira V P, Herbert A P, Cortés C et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.  J Immunol. 2009;  182(11) 7009-7018
    CrossrefPubMedSearch in Google Scholar
  • 32 Lehtinen M J, Rops A L, Isenman D E, van der Vlag J, Jokiranta T S. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.  J Biol Chem. 2009;  284(23) 15650-15658
    CrossrefPubMedSearch in Google Scholar
  • 33 Hirt-Minkowski P, Schaub S, Mayr M et al. Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option?.  Nephrol Dial Transplant. 2009;  24(11) 3548-3551
    CrossrefPubMedSearch in Google Scholar
  • 34 Olie K H, Goodship T H, Verlaak R et al. Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir.  Am J Kidney Dis. 2005;  45(1) e12-e15
    CrossrefPubMedSearch in Google Scholar
  • 35 Olie K H, Florquin S, Groothoff J W et al. Atypical relapse of hemolytic uremic syndrome after transplantation.  Pediatr Nephrol. 2004;  19(10) 1173-1176
    PubMedSearch in Google Scholar
  • 36 Richards A, Kavanagh D, Atkinson J P. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory states: the examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration.  Adv Immunol. 2007;  96 141-177
    PubMedSearch in Google Scholar
  • 37 Richards A, Kathryn Liszewski M, Kavanagh D et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.  Mol Immunol. 2007;  44(1-3) 111-122
    CrossrefPubMedSearch in Google Scholar
  • 38 Frémeaux-Bacchi V, Arzouk N, Ferlicot S, Charpentier B, Snanoudj R, Dürrbach A. Recurrence of HUS due to CD46/MCP mutation after renal transplantation: a role for endothelial microchimerism.  Am J Transplant. 2007;  7(8) 2047-2051
    CrossrefPubMedSearch in Google Scholar
  • 39 Kavanagh D, Richards A, Noris M et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome.  Mol Immunol. 2008;  45(1) 95-105
    CrossrefPubMedSearch in Google Scholar
  • 40 Conway E M, Nowakowski B. Biologically active thrombomodulin is synthesized by adherent synovial fluid cells and is elevated in synovial fluid of patients with rheumatoid arthritis.  Blood. 1993;  81(3) 726-733
    PubMedSearch in Google Scholar
  • 41 Józsi M, Strobel S, Dahse H M et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.  Blood. 2007;  110(5) 1516-1518
    CrossrefPubMedSearch in Google Scholar
  • 42 Le Quintrec M, Zuber J, Noel L H et al. Anti-factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome.  Am J Transplant. 2009;  9(5) 1223-1229
    CrossrefPubMedSearch in Google Scholar
  • 43 Kwon T, Dragon-Durey M A, Macher M A et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome.  Nephrol Dial Transplant. 2008;  23(6) 2088-2090
    CrossrefPubMedSearch in Google Scholar
  • 44 Donne R L, Abbs I, Barany P et al. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor.  Am J Kidney Dis. 2002;  40(6) E22
    CrossrefPubMedSearch in Google Scholar
  • 45 Bergstein J, Michael Jr A, Kellstrand C, Simmons R, Najarian J. Hemolytic-uremic syndrome in adult sisters.  Transplantation. 1974;  17(5) 487-490
    CrossrefPubMedSearch in Google Scholar
  • 46 Kaplan B S, Papadimitriou M, Brezin J H, Tomlanovich S J, Zulkharnain. Renal transplantation in adults with autosomal recessive inheritance of hemolytic uremic syndrome.  Am J Kidney Dis. 1997;  30(6) 760-765
    CrossrefPubMedSearch in Google Scholar
  • 47 Heinen S, Sanchez-Corral P, Jackson M S et al. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome.  Hum Mutat. 2006;  27(3) 292-293
    PubMedSearch in Google Scholar
  • 48 Kavanagh D, Goodship T H, Richards A. Atypical haemolytic uraemic syndrome.  Br Med Bull. 2006;  77–78 5-22
    PubMedSearch in Google Scholar
  • 49 Remuzzi G, Ruggenenti P, Codazzi D et al. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome.  Lancet. 2002;  359(9318) 1671-1672
    CrossrefPubMedSearch in Google Scholar
  • 50 Remuzzi G, Ruggenenti P, Colledan M et al. Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor H gene mutation.  Am J Transplant. 2005;  5(5) 1146-1150
    CrossrefPubMedSearch in Google Scholar
  • 51 Cheong H I, Lee B S, Kang H G et al. Attempted treatment of factor H deficiency by liver transplantation.  Pediatr Nephrol. 2004;  19(4) 454-458
    CrossrefPubMedSearch in Google Scholar
  • 52 Saland J M, Emre S H, Shneider B L et al. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation.  Am J Transplant. 2006;  6(8) 1948-1952
    CrossrefPubMedSearch in Google Scholar
  • 53 Saland J M, Shneider B L, Bromberg J S et al. Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.  Clin J Am Soc Nephrol. 2009;  4(1) 201-206
    CrossrefPubMedSearch in Google Scholar
  • 54 Jalanko H, Peltonen S, Koskinen A et al. Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H.  Am J Transplant. 2008;  8(1) 216-221
    PubMedSearch in Google Scholar
  • 55 Saland J M, Ruggenenti P, Remuzzi G. Consensus Study Group . Liver-kidney transplantation to cure atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2009;  20(5) 940-949
    CrossrefPubMedSearch in Google Scholar
  • 56 Nürnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  360(5) 542-544
    CrossrefPubMedSearch in Google Scholar
  • 57 Chatelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome.  Am J Transplant. 2009;  9(11) 2644-2645
    CrossrefPubMedSearch in Google Scholar
  • 58 Loirat C, Noris M, Frémeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children.  Pediatr Nephrol. 2008;  23(11) 1957-1972
    CrossrefPubMedSearch in Google Scholar
  • 59 Kavanagh D, Richards A, Frémeaux-Bacchi V et al. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome.  Clin J Am Soc Nephrol. 2007;  2(3) 591-596
    CrossrefPubMedSearch in Google Scholar
  • 60 Ariceta G, Besbas N, Johnson S European Paediatric Study Group for HUS et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.  Pediatr Nephrol. 2009;  24(4) 687-696
    CrossrefPubMedSearch in Google Scholar

David Kavanagh

Institute of Human Genetics, International Centre for Life, Central Parkway

Newcastle upon Tyne, NE1 3BZ United Kingdom

Email: davidkavanagh@doctors.org.uk